Trial of Docetaxel Versus Vinorelbine as 1st Line Treatment in Elderly Patients With Non-Small-Cell Lung Cancer (NSCLC)

Inclusion Criteria: * Histologically- or cytologically- confirmed Non-Small-Cell Lung Cancer * Stage IIIB/IV * No prior chemotherapy * Existence of two-dimensional measurable disease. The measurable disease should not have been irradiated * Life expectancy of more than 3 months * Age ≥ 65 years * Performance status (WHO) ≤ 3 * Adequate bone marrow function (absolute neutrophil count \> 1000/mm\^3, platelet count \> 100000/mm\^3, Hemoglobin \> 9 gr/mm\^3) * Adequate liver (bilirubin \< 1.5 times upper limit of normal and SGOT/SGPT \< 2 times upper limit of normal), and renal function (creatinine \< 2 mg/dl) * Informed consent Exclusion Criteria: * Psychiatric illness or social situation that would preclude study compliance. * Other concurrent uncontrolled illness * Other invasive malignancy within the past 5 years except nonmelanoma skin cancer * No absence or irradiated and stable central nervous system metastatic disease. * No presence of a reliable care giver * Other concurrent investigational agents